Kornimate/medical-research-clean huggingface dataset:
heart rate and cardiovascular diseases prognosis in people with stable coronary artery disease

Conditions: Stable Angina; Myocardial Infarction; Coronary Heart Disease; Heart Failure; Stroke; Death, Sudden, Cardiac; Peripheral Arterial Disease; Atrial Fibrillation; Bleeding

Summary: the cardiovascular disease research using linked bespoke studies and electronic records (caliber) e-health database was the data resource for this study. caliber links patient records from four different data sources: clinical practice research database (cprd), minap (myocardial ischaemia national audit project registry) hospital episodes statistics (hes), the office for national statistics (ons).

this study is part of the caliber (cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the nihr and wellcome trust. the central theme of the caliber research is linkage of the myocardial ischaemia national audit project (minap) with primary care (gprd) and other resources. the overarching aim of caliber is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. caliber has received both ethics approval (ref 09/h0810/16) and ecc approval (ref ecc 2-06(b)/2009 caliber dataset).

Eligibility criteria:
inclusion criteria: * aged \>=30 years at study entry -\>=1 year registration prior to the 'index date' exclusion criteria: * free from previous atherosclerotic events * no heart rate measurement after their 'index date' of eligibility to entry the study
ibd disease course of infliximab-naïve ibd patients treated with subcutaneous infliximab ct-p13 remsima®

Conditions: Inflammatory Bowel Diseases

Summary: current state of knowledge in view of the research about the condition under investigation inflammatory bowel diseases (ibd), including crohn's disease and ulcerative colitis, are chronic diseases characterized by relapsing and remitting episodes. about comparator strategies/procedures infliximab in its intravenous (iv) form was the first biotherapy to be approved to treat ibd. biosimilars of intravenous (iv) infliximab have been shown to be non-inferior to the reference product in patients with ibd, to induce and maintain clinical response recently, the subcutaneous (sc) formulation of the infliximab biosimilar ct-p13 (ct-p13 sc) has been shown to be non-inferior on ct-p13 concentration at week 22 to the iv formulation of ct-p13 (ct-p13 iv). these results were based on 66 patients treated with ct-p13 sc, and larger studies are needed to better assess ibd disease course of patients treated with ct-p13 sc in real-life setting.

the study assesses in real-life setting the ibd disease course of infliximab-naïve ibd patients treated with subcutaneous infliximab. this study will look at the clinical and biological outcomes of people who take subcutaneous infliximab. the study will enroll approximately 120 participants with an indication for iv infliximab. all participants will receive 1 intravenous infusion on day 1 and week 2, followed by 1 sc injection on week 6 and then 1 sc injection every 2 weeks for up to week 48. switch to subcutaneous infliximab (remsima® sc) at week 6 will be proposed as part of standard of care. this multi-center trial will be conducted in hospitals of assistance publique - hôpitaux de paris (ap-hp). the overall time to participate in this study is 48 weeks. participants will make approximately 5 visits to the clinic.

Eligibility criteria:
inclusion criteria: * diagnosis of crohn's disease or ulcerative colitis (confirmed by clinical evaluation and a combination of endoscopic, histological, radiological, and/or biochemical investigations according to european guidelines) * starting infliximab as standard of care (originator or biosimilars) * with or without concomitant immunosuppressive agent and/or steroids use at infliximab initiation * patients agreeing to participate exclusion criteria: * patients not eligible to infliximab according to standard of care screening * previous exposure to infliximab: originator or biosimilars * participation in another interventional study * no coverage by the french health insurance

Keywords: inflammatory bowel disease crohn disease colitis ulcerative infliximab
a quality improvement process to support delivery of cardiovascular care in community mental health organizations

Conditions: Diabetes Mellitus; Hypertension; Dyslipidemias

Summary: this pilot study will examine whether an implementation strategy will improve delivery of evidence-based care for cardiovascular risk factors for people with serious mental illness.

in this pilot study, the investigators will work with health home programs and pilot test an adapted comprehensive unit safety program (cusp) implementation strategy to improve mental health providers' delivery of evidence-based cardiovascular risk factor care for hypertension, dyslipidemia and diabetes for individuals with serious mental illness. the project will also characterize implementation processes, organizational and provider-level factors, and cardiovascular disease risk factor care and control.

Eligibility criteria:
inclusion criteria: study population 1: * psychiatric rehabilitation program and health home team staff, including providers and leadership are those employed by the psychiatric rehabilitation program or health home program. * english-speaking. study population 2: * people with serious mental illness participating in psychiatric rehabilitation health home programs. * english-speaking exclusion criteria: * none
yakima head start fluoride varnish study

Conditions: Dental Caries

Summary: the aim of this study is to determine whether an annual application of three (3) fluoride varnish doses over two weeks is at least as effective in reducing cavities as the current semi-annual application.

the study population will consist of pre-school aged children who are residents of yakima county, in central washington state. children will be recruited from non-migrant head start programs for ethnic minority farmworker children in the yakima valley. this study will be a randomized, double blinded trial with one experimental and one standard treatment group. each participant will be randomly assigned to one of two study groups. the participant and the personnel conducting the study will not know to which study group the participant was assigned. this trial has two study groups: 1. massive dose (experimental): annually for three years, children in the experimental group will receive three .30ml applications of 50mg naf/ml fluoride varnish (cavityshieldò, omni), followed 6 months later by three .30ml applications of placebo varnish in two weeks. there are 18 visits over the entire duration of the study. each participant will receive a dental exam annually. 2. semiannual dose (standard): annually for three years, children in the standard treatment group will receive one .30ml application of 50mg naf/ml fluoride varnish (cavityshieldò, omni) and two .30ml applications of placebo varnish in two weeks. they will receive this regimen again 6 months later. there are 18 visits over the entire duration of the study. each participant will receive a dental exam annually. both the experimental and standard treatment children will receive basic restorative dental care on decayed surfaces only, as well as toothbrushes for the duration of the study period. parents will fill out questionnaires about behaviors such as diet, hygiene and prior dental care. results will inform future treatment regimens for high-caries-risk populations.

Eligibility criteria:
inclusion criteria: * age 36-71 months * enrolled in participating head start center * plan to stay in yakima county for duration of the study * one sound tooth surface present exclusion criteria: * no teeth present * developmentally unable to give oral assent

Keywords: early childhood caries
rapamycine vs placebo for the treatment of inclusion body myositis

Conditions: Inclusion Body Myositis (IBM)

Summary: sporadic inclusion body myositis (ibm) is the most frequent inflammatory myopathy in patients over 50. it is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease. rapamycin used in organ transplantation blocks the activity of t effector cells, preserves t regulatory cells and induces autophagy (protein degradation), all parameters impaired during ibm. rapami is a prospective, randomised, controlled, double blind, monocentric, phase iib trial evaluating rapamycine against placebo.


Eligibility criteria:
inclusion criteria: * ibm defined by the benveniste \& hilton-jones ( neuromuscul disord. 2010;20: 414-21) or llyod criteria (neurology 2014; 83: 426-433) exclusion criteria: * impossiblility to walk 10 meters * hypersensitivity to rapamycin or one compound of the oral solution * severe respiratory insufficiency (fvc \< 50% and/or fev1 \< 50%) * severe chronic kidney disease (estimated glomerular filtration rate \ 0.3 g/24h) * chronic liver disease (cirrhosis and/or alt/ast \> 2.5 normal values) * cancer non in remission (necessitating specific treatment) during the past 12 months * connective tissue disease non in remission (necessitating specific treatment) during the past 12 months * pregnancy * seropositivity for hiv, hcv or hbv * total cholesterolemia \> 8 mmol/l * triglyceridemia \> 5 mmol/l * hemoglobinemia \< 11 g/dl * thrombopenia \< 100 000/mm3 * neutropenia \< 1500/ mm3 * lymphopenia \< 1000/ mm3
antimicrobial susceptibility testing guided triple therapy in salvage helicobacter pylori treatment

Conditions: Antimicrobial Susceptibility Testing; Triple Therapy

Summary: helicobacter pylori (h. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. strongly evidence supports that h. pylori eradication is an effective approach to reduce the incidence of those pathologies.


Eligibility criteria:
inclusion criteria: * consecutive patients who are 18-70 years old with persistent h. pylori infection after first or second line treatment attempts. exclusion criteria: * enable to undergo upper endoscopy; * patients with gastrectomy, acute gi bleeding and advanced gastric cancer; * known or suspected allergy to study medications; * taking bismuth and antibiotics in the previous four weeks, or taking proton pump inhibitor and h2-receptor blockers in the previous two weeks; * currently pregnant or lactating * inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Keywords: helicobacter pylori infection antimicrobial susceptibility testing (ast) triple therapy
the effect of breathing exercise and stabilization exercise with chronic low back pain

Conditions: Low Back Pain; Sleep Hygiene; Anxiety

Summary: the aim of this study is to compare the effect of sleep hygiene, breathing exercises, and stabilization exercises on pain, sleep quality, and anxiety level in patients with non-specific chronic low back pain.

addressing sleep problems in patients with chronic non-specific low back pain (lbp) can reduce chronic pain, the risk of developing depressive illness and improve pain-related quality of life. sleep is a concept that has physiological, psychological, and social dimensions. sleep is one of the essential and indispensable daily life activities that affect individuals' quality of life and well-being. decreasing pain is expected and likely to improve sleep quality. still, it is unknown what will happen due to improving sleep quality to resolve the pain of unknown origin. education about sleep hygiene with physiotherapy has not been assessed before on individuals with nonspecific lbp. since this training will require a lifestyle change, individuals should be warned not once but several times in a certain time, and this training should be reinforced. this will be an advantage for the patients receiving physiotherapy, and their therapists will support them in applying this training during the physiotherapy sessions. in our study, individuals with nonspecific chronic low back pain will be divided into three groups using the blinding method as part of a randomized controlled trial. the first group, as the conventional physical therapy group, will receive a hot pack and tens only. the second group, as the stabilization group, will receive lumbar stabilization exercises and the conventional physical therapy program. the third group, as the breathing exercise group, will receive breathing exercises, including sleep hygiene and stabilization group program.

Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-65 * having low back pain for at least the last 3 months * pain at 4 out of 10 according to vas (visual analogue scale) exclusion criteria: * radiculopathies * body mass index \> 35 * neurological, orthopedic, or cardiopulmonary diseases that will contraindicate exercise * treatment for pain in the last 3 months who have received * individuals who can't cooperate and those who have problems adapting to exercises

Keywords: nonspecific chronic low back pain sleep quality breathing exercises
sleep survey for medical trainees

Conditions: Sleep; Shift Work; Circadian Rhythm; Sleep Apnea; Insomnia

Summary: background this is a survey to understand sleep in the context of medical trainees (on call) and the participants knowledge about the relevance of sleep, shiftwork, and the impact that sleep may have on their working performance. the survey has been developed by sleep experts from america, europe, and africa, in collaboration with the world sleep society. it should take about 30-40 minutes to complete. the survey will focus on three different aspects, complemented by two standard questionnaires: 1. demographics and place of work 2. basic knowledge and perception of sleep 3. sleep routine 4. epworth sleepiness scale, insomnia sleep inventory


Eligibility criteria:
inclusion criteria: * medical staff * student / intern / fellow / resident / consultant * delivering on call work * any gender exclusion criteria: * non-medical staff working in hospitals from the wider multidisciplinary team * underage (less than 18 years)

Keywords: medical training on call working time
supplementation and depressive symptomatology incidence among saudi arabian adults

Conditions: Vitamin D Deficiency; Depressive Symptoms

Summary: the goal of this randomized controlled trial is to explore the relationship between vitamin d supplementation and depressive symptomatology in saudi arabian population. the main questions it aims to answer are: * is vitamin d deficiency associated with an increased prevalence of depressive symptomatology among saudi arabian population? * is vitamin d supplementation for a period of 3-month at 50,000 international units might be associated with an improved depressive status? all the participants were clients who attended the clinic to help with weight management - who were doing regular medical check-ups - at al themal medical center which is located in abha, saudi arabia. participants were requested to do a general blood test to check for any vitamins and minerals deficiencies as part of the routine clinical procedure. this procedure did not incur any additional costs on the behalf of the participants. the participants who were identified to have any deficiencies were recommended to take supplements, also as part of the routine clinical procedure. therefore, participants identified to be deficient or insufficient vitamin d levels were screened and recruited to participate in the current study. participants were randomly assigned to either an interventional (vitamin d) or placebo group (control). the interventional group received vitamin d supplementation of 50.000international units/week for 3 months and the placebo group received dietary advice and education on food sources of vitamin d for the same period. both groups received a weight gain or a weight loss diet as per their case. at the three-months follow-up, the participants were readministered the face-to-face questionnaire and their blood levels for vitamin d were also checked. thus, this study would add value to the actions taken to treat vitamin d deficiency in saudi arabian adults. this might also assist in approaching new recommendations related to preventing or treating depression via vitamin d supplementation.


Eligibility criteria:
inclusion criteria: * males and females aged between 18 and 65 years old * be vitamin d deficient/insufficient (as tested via blood levels) * have a bmi between 17kg/m2 \& 55 kg/m2 * able to understand arabic * able to provide written consent exclusion criteria: * participants already taking vitamin d supplements or anti-depressants * participants having normal vitamin d levels * participants reporting other mental health diseases * pregnant or lactating women.
primary patency in post-angioplasty dysfunctional arteriovenous fistula in renal dialysis: paclitaxel-releasing pta balloon catheter vs pta balloon

Conditions: Arteriovenous Fistula Renal Dialysis Devices Obstruction

Summary: in recent years the use of paclitaxel releasing percutaneous transluminal angioplastic (pta) balloon catheter is spreading in vascular pathology, mainly in stenosis infrainguinal arteries. this device combined the mechanical action of pta balloon with the antiproliferative effects of paclitaxel. the use of these devices in venous pathology is limited. this devices could improve the treatment of renal dialysis arteriovenous fistula stenosis.


Eligibility criteria:
inclusion criteria: * patient with renal dialysis with arteriovenous fistula (avf) at least 3 months before. * patient diagnosed with avf stenosis by clinical and radiological criteria * sign informed consent exclusion criteria: * pregnant or breastfeeding * patients with avf stenosis not could be treated with pta catheter * paclitaxel allergy * iodinated contrast allergy * local or systemic active infection * life expectancy less than 12 moths

Keywords: vascular access devices obstruction
rapid urease test for diagnosis of h. pylori infection in patients with peptic ulcer bleeding

Conditions: Peptic Ulcer; Hemorrhage

Summary: rapid urease test (rut) is the most commonly used biopsy-based method to diagnose helicobacter pylori (hp) infection because of its simple, rapid and accurate characters. however, its sensitivity was reported to decrease during ulcer bleeding recently. so it is an important issue to avoid a false negative test in these patients. siddique et al reported that the sensitivity of rut could be increased when the biopsy number increased from 1 to 4. other studies demonstrated that additional biopsy from gastric body would increased the sensitivity of rut in patients with ulcer bleeding. therefore, we design this study to see if increased number of biopsy or different location of biopsy could increase sensitivity of rut in patients with gastroduodenal ulcer bleeding. after receiving explanation and giving consent, these patients with gastric or duodenal ulcer bleeding diagnosed after endoscopic examination will be enrolled. those who are unstable, have received antibiotic or continuous proton pump inhibitor treatment within 4 weeks, or are contraindicated for endoscopic biopsy will be excluded. we will take 1 piece, 4 pieces of biopsy samples from prepyloric antrum and 1 piece from gastric body with standard biopsy forceps from the patients after they agree for rut test. then, we put these samples into 3 separate rut kits respectively. we use 13c-ubt as gold standard for diagnosis of hp infection. it is scheduled: (1) if the condition of this patient is not suitable for breath test just after endoscopic examination, 13c-ubt will be performed within 2 days,(2) otherwise, it will be performed 1 hour after examination. we plan to enroll 100 patients for this study. we will apply mcnamer's test to examine the difference of rut sensitivity of different biopsy number. for the rut sensitivity from different locations, we use kappa statistic method to analyze their consistency.

as brief summary

Eligibility criteria:
inclusion criteria: * gastroduodenal ulcer with bleeding, documented by endoscopic examination exclusion criteria: * 1. receiving continuous proton pump inhibitor treatment, antibiotics within 4 weeks 2. not suitable for endoscopic biopsy 3. hemodynamically unstable

Keywords: peptic ulcer hemorrhage rapid urease test urea breath test
the study of wuling capsule in treatment chronic tinnitus

Conditions: Tinnitus, Subjective

Summary: to evaluate the effect of psychological/mental factors on the severity of subjective tinnitus, to observe the efficacy and safety of wuling capsule in the treatment of chronic subjective tinnitus with emotional disorders, and to evaluate the control rate of tinnitus complications, such as depression, anxiety and insomnia, and the improvement of patients'quality of life.

to evaluate the effect of psychological/mental factors on the severity of subjective tinnitus, to observe the efficacy and safety of wuling capsule in the treatment of chronic subjective tinnitus with emotional disorders, and to evaluate the control rate of tinnitus complications, such as depression, anxiety and insomnia, and the improvement of patients'quality of life. patients with chronic tinnitus complicated with mild to moderate anxiety or depression were randomly divided into two groups. the experimental group was given oral treatment with wuling capsule, and the control group was given gurusu treatment. the improvement of tinnitus, sleep, anxiety and depression in patients was evaluated at 2,4 and 8 weeks after treatment, respectively, and the efficacy of wuling capsule in improving tinnitus combined with anxiety, depression and tinnitus was analyzed。

Eligibility criteria:
inclusion criteria: * tinnitus with a history longer than 6 months; * 7 \< hamd score \< 24 and / or 7 \< hama score \< 21; * no antianxiety, depression or antipsychotic treatment within 2 weeks. exclusion criteria: * objective tinnitus; * tinnitus with defined causes; * accompanied with acute infection, acute trauma, perioperative, chronic disease in the acute stage; * with mental illness family history; * hamd score greater than 24 points or hama score greater than 21 points;